Ed Natoli

Ed Natoli has a significant work experience in the field of biosciences and pharmaceuticals. Ed started their career at Pfizer in 1998 as a Scientist in the Therapeutic & Reagent Monoclonal Core Facility, where they were responsible for purifying and characterizing therapeutic monoclonal antibodies.

In 2005, they continued their work at Pfizer as a Scientist in Early Discovery Toxicology, focusing on the early stages of drug development.

From 2009 to 2016, Ed worked at Kolltan Pharmaceuticals, Inc. as a Scientist in the Department of Bioprocess Development. During this time, they managed the protein purification research facility and was involved in various aspects of monoclonal antibody process, from screening hybridoma clones to purifying preclinical lots.

In 2017, Ed joined Assembly Biosciences, Inc. as a Scientist II in Drug Substance Development. Ed was responsible for large scale production and processing of anaerobic bacteria and had proficiency in operating bioreactors and anaerobic chambers.

Currently, Ed is working at Artizan Biosciences, Inc. as a Senior Scientist in Mechanistic Research. Ed'srole involves production of antibodies for potential therapeutic agents in Inflammatory Bowel Disease, development of in vitro quantitate ELISA, and evaluation of therapeutic agents in murine models of IBD.

Throughout their career, Ed has shown expertise in various areas of research and development in the biosciences field.

Ed Natoli holds a Master's degree in Immunology from Queen College. The dates of their enrollment and graduation are not specified.